💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Semaglutide

CHEMBL2108724 Phase 4 معتمد Protein
Half-Life
7 days
Bioavailability
—
Protein Binding
—
Molecular Weight
4114.0 g/mol
LogP
-5.8
Phase
4

Mimicking a natural gut hormone called GLP-1, this injectable or oral medication stimulates insulin release, reduces appetite, and slows stomach emptying, leading to better blood sugar control and meaningful weight loss. It has also been shown to reduce the risk of serious cardiovascular events such as heart attack and stroke in people with established heart disease.

الوزن الجزيئي

4114,0000 g/mol

LogP

-5,80

TPSA

1650,00 Ų

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Glaucoma Cardiovascular Disease Pain Management Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Schizophrenia Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Type 2 Diabetes Hypertension Major Depressive Disorder HIV/AIDS Heart Failure Atrial Fibrillation Prostate Cancer

تصنيفات الأدوية

A — A - Alimentary Tract and Metabolism

آلية العمل

GLP-1 receptor agonist with enhanced albumin binding for extended action.

Pharmacokinetics (PK)

Half-Life 7 days

Pharmacodynamics (PD)

الآلية

GLP-1 receptor agonist with enhanced albumin binding for extended action.

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N

InChI

InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1

Molecular Formula

C187H291N45O59

HBD / HBA

57 / 63

الروابط القابلة للدوران

151

الذرات الثقيلة

291

PPARG (Peroxisome Proliferator-Activated Receptor Gamma) Agonist
Primary Target
MTOR (Mechanistic Target of Rapamycin) Other
Moderate Semaglutide + Warfarin

Semaglutide slows gastric emptying, potentially reducing and delaying oral warfarin absorption, leading to variable changes in INR that complicate anticoagulation management.
Moderate Semaglutide + Insulin Glargine

Combining semaglutide with insulin glargine increases hypoglycaemia risk; however, the combination is used clinically with appropriate dose adjustments for improved glycaemic control.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Mimicking a natural gut hormone called GLP-1, this injectable or oral medication stimulates insulin release, reduces appetite, and slows stomach emptying, leading to better blood sugar control and meaningful weight loss. It has also been shown to reduce the risk of serious cardiovascular events such as heart attack and stroke in people with established heart disease.

GLP-1 receptor agonist with enhanced albumin binding for extended action.

Key pharmacokinetic parameters for Semaglutide: Half-life: 7 days.

Yes, Semaglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

ADME Journey →

Related Drugs

Same Drug Class

Metformin Small molecule Omeprazole Small molecule Pantoprazole Small molecule Lansoprazole Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108724. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56843331. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.